Rupatadine
Rupatadine is a second-generation antihistamine with dual H1 receptor antagonist and platelet-activating factor (PAF) receptor antagonist activity, used for the treatment of allergic rhinitis and chronic urticaria, with some investigation in rheumatoid arthritis-related pruritus. By blocking both histamine H1 receptors and PAF receptors, it provides broader anti-allergic and anti-inflammatory effects than selective antihistamines. It has low sedation potential due to limited CNS penetration.
Peso molecular
416,0000 g/mol
LogP
5,80
TPSA
29,00 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estructura 2D
Cite this structure
Embed this structure
SMILES
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1
InChI
InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3
Molecular Formula
C26H26ClN3
HBD / HBA
- / 3
Enlaces Rotables
2
Átomos Pesados
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Rupatadine is a second-generation antihistamine with dual H1 receptor antagonist and platelet-activating factor (PAF) receptor antagonist activity, used for the treatment of allergic rhinitis and chronic urticaria, with some investigation in rheumatoid arthritis-related pruritus. By blocking both histamine H1 receptors and PAF receptors, it provides broader anti-allergic and anti-inflammatory effects than selective antihistamines. It has low sedation potential due to limited CNS penetration.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Rupatadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL91397. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 133017. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rupatadine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rupatadine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rupatadine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rupatadine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rupatadine"></drugfyi-drug>